Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free CALT Stock Alerts

Calliditas Therapeutics AB (publ) (CALT) Competitors

Calliditas Therapeutics AB (publ) logo
$40.00 0.00 (0.00%)
As of 06/12/2026
Compare

CALT vs. LEGN, NNNN, EWTX, ERAS, and INDV

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? MarketBeat compares Calliditas Therapeutics AB (publ) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calliditas Therapeutics AB (publ) include Legend Biotech (LEGN), Anbio Biotechnology (NNNN), Edgewise Therapeutics (EWTX), Erasca (ERAS), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

How does Calliditas Therapeutics AB (publ) compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Legend Biotech had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Legend Biotech and 0 mentions for Calliditas Therapeutics AB (publ). Legend Biotech's average media sentiment score of 0.90 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Legend Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Legend Biotech Positive
Calliditas Therapeutics AB (publ) Neutral

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Legend Biotech presently has a consensus price target of $60.23, suggesting a potential upside of 67.91%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.67
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Legend Biotech has a net margin of -21.98% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Legend Biotech's return on equity of -24.92% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-21.98% -24.92% -14.87%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$1.03B6.48-$296.80M-$0.68N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Legend Biotech has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

Legend Biotech beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Anbio Biotechnology has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anbio Biotechnology$8.65M259.33$6.40MN/AN/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Anbio Biotechnology has a beta of 4.4, indicating that its share price is 340% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, Anbio Biotechnology had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Anbio Biotechnology and 0 mentions for Calliditas Therapeutics AB (publ). Anbio Biotechnology's average media sentiment score of 1.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
Anbio Biotechnology Very Positive
Calliditas Therapeutics AB (publ) Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Anbio Biotechnology has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Anbio Biotechnology's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Anbio BiotechnologyN/A N/A N/A
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

Summary

Anbio Biotechnology beats Calliditas Therapeutics AB (publ) on 9 of the 12 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Edgewise Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/A-$167.79M-$1.66N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Edgewise Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Edgewise Therapeutics' average media sentiment score of 1.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Edgewise Therapeutics Very Positive
Calliditas Therapeutics AB (publ) Neutral

Edgewise Therapeutics currently has a consensus price target of $44.22, suggesting a potential upside of 26.97%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Edgewise Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edgewise Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Edgewise Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Edgewise Therapeutics' return on equity of -32.55% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Edgewise TherapeuticsN/A -32.55% -31.04%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

Summary

Edgewise Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Erasca?

Erasca (NASDAQ:ERAS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Erasca has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Erasca's return on equity of -35.31% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
ErascaN/A -35.31% -29.49%
Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96%

Erasca has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

67.8% of Erasca shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Erasca had 24 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 24 mentions for Erasca and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 beat Erasca's score of -0.20 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.

Company Overall Sentiment
Erasca Neutral
Calliditas Therapeutics AB (publ) Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Erasca. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ErascaN/AN/A-$124.55M-$0.93N/A
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A

Erasca currently has a consensus price target of $20.11, suggesting a potential upside of 43.14%. Given Erasca's stronger consensus rating and higher probable upside, research analysts plainly believe Erasca is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Erasca
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Erasca beats Calliditas Therapeutics AB (publ) on 10 of the 15 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Indivior has a consensus price target of $39.33, suggesting a potential upside of 2.22%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Indivior
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Indivior had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 0.73 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the news media.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
Indivior Positive

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Indivior has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
Indivior$1.24B3.79$210M$1.9519.73

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Indivior has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Indivior has a net margin of 19.44% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
Indivior 19.44%-219.26%29.40%

Summary

Indivior beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALT vs. The Competition

Export
MetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.19B$979.54M$6.52B$12.05B
Dividend YieldN/A4.84%2.67%5.66%
P/E Ratio-21.621.4524.0024.42
Price / Sales0.74120.49516.42110.81
Price / CashN/A20.0627.4837.92
Price / Book37.747.8510.746.82
Net Income-$43.96M-$4.88M$3.57B$337.56M
7 Day PerformanceN/A0.64%0.58%1.16%
1 Month PerformanceN/A-0.16%1.48%3.16%
1 Year PerformanceN/A47.51%25.41%30.60%

Calliditas Therapeutics AB (publ) Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat		N/AN/A$1.19B$1.60BN/A180
LEGN
Legend Biotech
4.2378 of 5 stars		$36.28
+42.2%		$59.15
+63.0%		-2.6%$4.74B$1.03BN/A2,965
NNNN
Anbio Biotechnology
1.54 of 5 stars		$32.12
+6.5%		N/AN/A$4.34B$8.65MN/A27
EWTX
Edgewise Therapeutics
2.9637 of 5 stars		$37.25
-7.5%		$44.22
+18.7%		+127.8%$4.33BN/AN/A60
ERAS
Erasca
2.1632 of 5 stars		$13.48
-2.5%		$18.75
+39.1%		+849.3%$4.30BN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel